New Hope: Stem Cell Trial Improves Age-Related Frailty
In a Phase 2b randomized, dose-finding study of 148 ambulatory adults with aging-related frailty, intravenous laromestrocel improved six-minute walk...
ITM Reveals New pNETs Analysis from COMPETE Trial at ENETS
Phase 3 COMPETE met its primary endpoint, with 177Lu-edotreotide delivering a clinically and statistically significant improvement in progression-free survival...
Tempest Reveals Emerging Data From TPST-2003 Redeem-1 Study
TPST-2003 delivered a 100% complete response rate among the six efficacy-evaluable patients in the ongoing REDEEM-1 Phase 1/2a trial,...
Bridging the Cognitive Gap: How Novo Nordisk is Virtualizing Clinical Trial Decisions
The pharmaceutical industry has long grappled with the cognitive dissonance of drug development—the tension between data-driven insights and the...
Crescent BioPharma Doses First Patient in CR-001 Tumor Trial
Crescent Biopharma has dosed the first patient in ASCEND (NCT07335497), a global, open-label Phase 1/2 trial of CR-001, a...
Starton Doses First Patient in Phase 2a Myeloma Study
In a small Phase 1b study of six relapsed/refractory multiple myeloma patients, continuous low‑dose lenalidomide (STAR-LLD) produced one complete...
Klothea Bio Launches mRNA Trial for Lifespan Extension
Klothea Bio has initiated a randomized, double-blind, placebo-controlled Phase 1b study of AKL003, an intravenous alpha Klotho mRNA therapeutic...
PDS Biotech Amends Phase 3 Trial for Accelerated Approval
PDS Biotechnology has amended its Phase 3 VERSATILE-003 trial to add progression-free survival as an interim primary endpoint to...
FDA Approves Phase 2 Trial for Daré’s Promising HPV Drug
FDA has cleared Daré Bioscience’s IND for DARE-HPV, a fixed-dose lopinavir/ritonavir vaginal insert, enabling a Phase 2 study in...
Cyclerion Advances CYC-126 Phase 2 Study With FDA Feedback
Cyclerion received positive written FDA feedback on its planned Phase 2 proof‑of‑concept study of CYC‑126 in treatment‑resistant depression, with...